



## Supporting Information

for

### New one-pot synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones based on 5-aminopyrazoles and azlactones

Vladislav Yu. Shuvalov, Ekaterina Yu. Vlasova, Tatyana Yu. Zheleznova  
and Alexander S. Fisyuk

*Beilstein J. Org. Chem.* **2023**, *19*, 1155–1160. doi:10.3762/bjoc.19.83

### Experimental procedures, characterization data, and $^1\text{H}$ and $^{13}\text{C}$ NMR spectra for all new compounds

## **Table of contents**

|   |     |
|---|-----|
| General information.....                            | S2  |
| Compounds characterization and analytical data..... | S3  |
| References.....                                     | S8  |
| Copies of NMR spectra.....                          | S10 |


## General information

<sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired on a Bruker DRX-400 spectrometer (working frequencies 400 and 100 MHz, respectively) in CDCl<sub>3</sub> or DMSO-d<sub>6</sub>, with the residual solvent signals (CDCl<sub>3</sub>: 7.26 ppm for <sup>1</sup>H nuclei and 77.0 ppm for <sup>13</sup>C nuclei; DMSO-d<sub>6</sub>: 2.50 ppm for <sup>1</sup>H nuclei and 39.5 ppm for <sup>13</sup>C nuclei) serving as internal standards. All chemical shifts ( $\delta$ ) are reported in ppm and coupling constants ( $J$ ) in Hz. Absorption spectra were recorded on a PerkinElmer Lambda 750 diode array spectrophotometer, photoluminescence spectra were recorded on a Cary Eclipse fluorescence spectrophotometer. In both cases, the test compounds were dissolved in EtOH so that the concentration of the resulting solutions was lower than 10<sup>-5</sup> mol/dm<sup>3</sup>. The molar light absorption coefficient was determined according to the described method [1,2]. The quantum yield was determined relative to quinine sulfate in 0.5 M H<sub>2</sub>SO<sub>4</sub> ( $\Phi_f$  0.546) using the comparison method [3,4]. Infra-red spectra were recorded on an Infracam FT-801 spectrometer for others in KBr pellets. The elemental analyses were carried out on a Carlo Erba 1106 CHN analyzer. The melting points were determined on a Reichert RD-MP. Monitoring of the reaction progress and assessment of the purity of synthesized compounds were done by TLC on Silufol UV-254 plates, eluents CHCl<sub>3</sub>–EtOAc, 10:1. Visualization of plates was done under UV light. Silica gel 60 (0.063–0.200 mm, Macherey–Nagel) was used for column chromatography.

The starting compounds **1** [5], **2a–i** [6–10], **5** [11] and **6** [12] were prepared following the reported methods.

## Compounds characterization and analytical data


### *N*-(3-Methyl-6-oxo-1,4-diphenyl-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)benzamide (3a).



**(3a).** A mixture of 3-methyl-1-phenyl-1*H*-pyrazol-5-amine (**1**, 346 mg, 2 mmol) and 4-benzylidene-2-phenyloxazol-5(4*H*)-one (**2a**, 498 mg, 2 mmol) was heated at 150 °C for 40 min, after cooling to room temperature, the product was purified by column chromatography on silica gel (eluent, CHCl<sub>3</sub>–EtOAc, 10:1). Yield: 523 mg (62%), colorless crystals, m.p. >250 °C (*i*-PrOH) (m.p. 268–270 °C (EtOH) [13]). IR (KBr): 3295, 3194, 3062, 3032, 2911, 1698, 1693, 1642, 1601, 1582, 1547, 1496, 1457, 1374, 1357, 1335, 1267, 1255, 1184, 1113, 1075, 1054, 1026, 1002, 916, 819, 800, 754, 694, 660 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.46 (s, 3H), 4.40 (d, *J* = 11.9 Hz, 1H), 5.05 (dd, *J* = 11.9, 9.0 Hz, 1H), 7.20–7.26 (m, 1H), 7.31–7.39 (m, 5H), 7.40–7.45 (m, 2H), 7.48–7.53 (m, 3H), 7.55–7.59 (m, 2H), 7.71–7.74 (m, 2H), 8.68 (d, *J* = 9.0 Hz, 1H), 10.79 (s, 1H), <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ: 12.5, 41.4, 56.0, 102.3, 122.9, 126.8, 127.1, 127.2, 128.2, 128.3, 128.5, 129.2, 131.3, 134.1, 137.3, 137.9, 140.1, 145.5, 166.4, 168.5. Anal. Calcd for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C 73.92, H 5.25, N 13.26. Found: 73.80, H 5.30, N 13.15.

**General procedure for the synthesis of 3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4a–i).** A mixture of 3-methyl-1-phenyl-1*H*-pyrazol-5-amine (**1**, 346 mg, 2 mmol) and azlactones **2a–i** (2 mmol) was heated at 150 °C for 40 min. Then the mixture was cooled and DMSO (4 mL) and *t*-BuOK (336 mg, 3 mmol) was added, after which the resulting mixture was heated at 150 °C for 1.5 h. The reaction mixture was cooled, poured into H<sub>2</sub>O (30 mL), and 10% HCl was added on cooling to pH ≈ 3. The precipitate formed was filtered off, dried, and purified by column chromatography on silica gel (eluent, CHCl<sub>3</sub>–EtOAc, 10:1).


**3-Methyl-1,4-diphenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4a).** Yield: 439 mg



(73%), colorless crystals, m.p. 194-195 °C (m.p. 193-194 °C [14]). IR (KBr): 3056, 1634, 1599, 1586, 1568, 1512, 1503, 1495, 1472, 1457, 1443, 1426, 1402, 1383, 1352, 1316, 1258, 1248, 1213, 1161, 1121, 1082, 1021, 986, 889, 860, 847, 776, 762, 725, 706, 696, 679, 637 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)

δ: 2.09 (s, 3H), 6.34 (s, 1H), 7.14-7.18 (m, 1H), 7.26-7.32 (m, 2H), 7.43-7.52 (m, 5H), 7.61-7.67 (m, 2H), 11.01 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 14.7, 107.3, 110.2, 122.2, 126.8, 128.3, 128.4, 129.0, 129.0, 137.1, 137.5, 143.9, 144.0, 150.6, 163.6. Anal. Calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O: C 75.73, H 5.02, N 13.94. Found: C 75.88, H 5.14, N 13.80.


**4-(4-Chlorophenyl)-3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4b).**



Yield: 470 mg (70%), colorless crystals, m.p. 228-229 °C. IR (KBr): 3056, 1647, 1642, 1595, 1576, 1503, 1429, 1383, 1348, 1281, 1262, 1159, 1121, 1090, 1015, 988, 887, 862, 830, 760, 731, 714, 691, 675 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.10 (s, 3H), 6.30 (s, 1H), 7.16-7.21 (m, 1H), 7.29-7.34 (m, 2H), 7.36-7.41 (m, 2H), 7.46-7.52 (m, 2H), 7.60-7.65 (m, 2H), 10.84 (br.s, 1H). <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>) δ: 14.8, 107.0, 110.3, 122.2, 127.0, 128.7, 129.1, 129.7, 135.2, 135.5, 137.4, 143.8, 143.9, 149.2, 163.4. Anal. Calcd for C<sub>19</sub>H<sub>14</sub>ClN<sub>3</sub>O: C 67.96, H, 4.20, N 12.51. Found: C 67.82, H, 4.11, N 12.34.

**4-(4-Methoxyphenyl)-3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one**




(4c). Yield: 384 mg (58%), colorless crystals, m.p. 188-189 °C. IR (KBr): 3063, 1632, 1597, 1586, 1574, 1503, 1387, 1356, 1252, 1211, 1159, 1090, 1015, 980, 889, 858, 835, 764, 733, 696 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: . 2.15 (s, 3H), 3.88 (s, 3H), 6.30 (s, 1H), 6.99-7.04 (m, 2H), 7.11-7.17 (m, 1H), 7.26-7.31 (m, 2H), 7.37-7.41 (m, 2H), 7.59-7.64 (m, 2H), 10.85 (br.s, 1H). <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>) δ: 15.0, 55.3, 107.3, 110.1, 113.8, 122.2, 126.9, 129.0, 129.4, 129.7, 137.5,


143.8, 144.1, 150.5, 160.3, 163.6. Anal. Calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>: C 72.49, H 5.17, N 12.68. Found: C 72.34, H 5.13, N 12.79.

**4-(3,4-Dimethoxyphenyl)-3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4d).**



**one (4d).** Yield: 397 mg (55%), colorless crystals, m.p. 243-244 °C. IR (KBr): 3069, 1634, 1607, 1599, 1582, 1514, 1429, 1356, 1221, 1159, 1115, 1015, 980, 862, 839, 799, 733, 698 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 2.19 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 6.47 (s, 1H), 7.04-7.11 (m, 2H), 7.13 (s, 1H), 7.28 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.8 Hz, 2H), 8.21 (d, J = 7.8 Hz, 2H), 11.39 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ: 15.3, 55.5, 55.6, 106.0, 109.2, 111.4, 112.5, 120.5, 121.3, 125.2, 128.9, 129.4, 139.3, 142.3, 148.3, 148.4, 149.3, 150.0, 163.4. Anal. Calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>: C 69.79, H 5.30, N 11.63. Found: C 69.60, H 5.19, N 11.48.

**3-Methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4e).**



**one (4e).** Yield: 438 mg (56%), colorless crystals, m.p. 184-185 °C. IR (KBr): 3061, 3001, 2928, 2835, 1644, 1582, 1574, 1509, 1468, 1455, 1410, 1356, 1325, 1237, 1179, 1131, 1003, 828, 760, 731, 693 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.19 (s, 3H), 3.89 (s, 6H), 3.92 (s, 3H), 6.34 (s, 1H), 6.66 (s, 2H), 7.18-7.23 (m, 1H), 7.31-7.36 (m, 2H), 7.65-7.68 (m, 2 H), 10.70 (br.s, 1H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 15.0, 56.2, 61.0, 105.8, 107.2, 110.1, 122.2, 127.0, 129.2, 132.5, 137.5, 138.7, 143.9, 144.0, 150.5, 153.1, 163.4. Anal. Calcd for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>: C 67.51, H 5.41, N 10.74. Found: C 67.66, H 5.19, N 10.83.

**4-(4-Fluorophenyl)-3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4f).**

Yield: 427 mg (67%), colorless crystals, m.p. 239-240 °C. IR (KBr): 3075, 1632, 1582, 1514, 1429, 1389, 1356, 1266, 1252, 1221, 1157, 1115, 1015, 780, 924, 899, 862, 857, 839, 799, 764, 731, 696, 675, 569 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.10 (s, 3H), 6.31 (s, 1H), 7.16-7.24 (m, 3H), 7.31-7.37 (m, 2H), 7.39-7.45 (m, 2H), 7.63-7.67 (m, 2H), 10.50 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 14.8, 107.2, 110.3, 115.5 (d, *J* = 21.6 Hz), 122.3, 127.0, 129.2, 130.2 (d, *J* = 7.8 Hz), 133.1 (d, *J* = 3.5 Hz), 137.5, 143.8, 144.0, 149.5, 163.2 (d, *J* = 248.8 Hz), 163.3. Anal. Calcd for C<sub>19</sub>H<sub>14</sub>FN<sub>3</sub>O: C 71.46, H 4.42, N 13.16. Found: C 71.32, H 4.54, N 12.99.


**3-Methyl-1-phenyl-4-(*p*-tolyl)-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4g).** Yield:

441 mg (70%), colorless crystals, m.p. 217-218 °C. IR (KBr): 3060, 1642, 1584, 1516, 1497, 1428, 1383, 1348, 1266, 1210, 1183, 1159, 1119, 1011, 984, 851, 824, 762, 729, 693 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.12 (s, 3H), 2.45 (s, 3H), 6.31 (s, 1H), 7.12-7.17 (m, 1H), 7.26-7.36 (m, 6H), 7.59-7.63 (m, 2H), 10.90 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 14.9, 21.3, 107.2, 110.2, 122.2, 126.9, 128.3, 129.0 (3C), 134.2, 137.4, 139.0, 143.8, 144.1, 150.8, 163.6. Anal. Calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O: C 76.17, H 5.43, N 13.32. Found: C 76.54, H 5.53, N 13.12.

**4-(Furan-2-yl)-3-methyl-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4h).**

Yield: 338 mg (58%), colorless crystals, m.p. 188-189 °C. IR (KBr): 3048, 1597, 1580, 1557, 1511, 1493, 1418, 1387, 1343, 1277, 1267, 1204, 1175, 1157, 1140, 1038, 1015, 957, 858, 820, 776, 764, 752, 727, 696, 658, 658, 598 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.57 (s, 3H), 6.57 (m, 2H), 6.92 (d, *J* = 3.3 Hz, 1H), 7.12 (t, *J* = 7.4 Hz, 1H), 7.24 (t, *J* = 7.7 Hz, 2H), 7.57-7.61 (m, 2H), 7.66 (d, *J* = 1.2 Hz, 1H), 10.54 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 16.0, 105.2, 106.4, 111.8, 112.2, 122.2, 126.9, 128.9, 137.3, 137.7, 144.0, 144.1, 145.1, 150.4, 163.4. Anal. Calcd for C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>: C 70.09, H 4.50, N 14.42. Found: C 70.19, H 4.41, N 14.28.


**3-Methyl-1-phenyl-4-(thiophen-2-yl)-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (4i).**



Yield: 368 mg (60%), colorless crystals, m.p. 190-191 °C. IR (KBr): 3069, 1642, 1597, 1572, 1511, 1497, 1439, 1385, 1354, 1333, 1219, 1213, 1183, 1138, 1080, 1038, 1026, 1013, 976, 909, 849, 806, 799, 758, 727, 712, 694, 666 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 2.32 (s, 3H), 6.54 (s, 1H), 7.23-7.31 (m, 2H), 7.45-7.54 (m, 3H), 7.78 (d, *J* = 5.0 Hz, 1H), 8.17 (d, *J* = 7.7 Hz, 2H), 11.36 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ: 15.3, 106.6, 108.6, 120.7, 125.5, 127.9, 128.2, 128.9, 129.2, 137.2, 139.1, 140.6, 142.1, 150.1, 163.4. Anal. Calcd for C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>OS: C 66.43, H 4.26, N 13.67. Found: C 66.33, H 4.38, N 13.53.


**3-Methyl-4-phenyl-1-(*p*-tolyl)-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one (9a).** Yield:

473 mg (75%), colorless crystals, m.p. 188-189 °C. IR (KBr): 3063, 1640, 1605, 1593, 1582,



1566, 1520, 1493, 1445, 1381, 1347, 1302, 1286, 1271, 1246, 1217, 1179, 1159, 1144, 1109, 1078, 1021, 990, 924, 860, 845, 820, 795, 766, 702, 667, 642, 615 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.08 (s, 3H), 2.25 (s, 3H), 6.34 (s, 1H), 7.05 (d, *J* = 8.2 Hz, 2H), 7.42-7.55 (m, 7H), 10.91 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 14.7, 21.0, 106.9, 110.3, 122.1, 128.3, 128.4, 129.0, 129.5, 134.8, 136.9, 137.2, 143.5, 143.7, 150.7, 163.6. Anal. Calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O: C 76.17, H 5.43, N 13.32. Found: C 76.48, H 5.50, N 13.16.

**3-Methyl-1-(naphthalen-2-yl)-4-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one**



**(10a).** Yield: 394 mg (56%), colorless crystals, m.p. 224-225 °C. IR (KBr): 3050, 1640, 1634, 1603, 1566, 1514, 1499, 1474, 1443, 1387, 1352, 1286, 1557, 1131, 1075, 1017, 887, 858, 814, 774, 747, 749, 760 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.90 (s, 3H), 6.43 (s, 1H), 7.31-7.43 (m, 4H), 7.49-7.54 (m, 4H), 7.58 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.65-7.70 (m, 2H), 7.93 (d, *J* = 1.8 Hz, 1H), 12.04 (br.s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 14.7, 107.5, 109.7, 118.3, 120.8, 125.7, 126.5, 127.4, 127.5, 128.3, 128.4, 128.8, 129.0, 131.5, 132.7, 134.8,


137.0, 143.7, 143.9, 150.8, 164.3. Anal. Calcd for C<sub>23</sub>H<sub>17</sub>N<sub>3</sub>O: C 78.61, H 4.88, N 11.96. Found: C 78.47, H 4.92, N 12.01.

## References


1. Kumar, A.; Singh, S.; Singh Mudahar, G.; Singh Thind, K. *Radiat. Phys. Chem.* **2006**, *75*, 737–740. doi:10.1016/j.radphyschem.2005.12.035
2. Williams, A. T. R.; Winfield, S. A.; Miller, J. N. *Analyst* **1983**, *108*, 1067. doi:10.1039/an9830801067
3. Allen, M. W. *Measurement of Fluorescence Quantum Yields*; Thermo Fisher Scientific: Madison. Technical note: 52019.
4. Brouwer, A. M. *Pure Appl. Chem.* **2011**, *83*, 2213–2228. doi:10.1351/PAC-REP-10-09-31
5. Ganesan, A.; Heathcock, C. H. J. *Org. Chem.* **1993**, *58*, 6155–6157. doi:10.1021/jo00074a058
6. Shuvalov, V. Yu.; Rozhkova, Yu. S.; Plekhanova, I. V.; Kostyuchenko, A. S.; Shklyaev, Yu. V.; Fisyuk, A. S. *Chem. Heterocycl. Compd.* **2022**, *58*, 7–14. doi:10.1007/s10593-022-03050-5
7. Shuvalov, V. Yu.; Chernenko, S. A.; Shatsauskas, A. L.; Samsonenko, A. L.; Dmitriev, M. V.; Fisyuk, A. S. *Chem. Heterocycl. Compd.* **2021**, *57*, 764–771. doi:10.1007/s10593-021-02980-w
8. Pinheiro, D. L. J.; Nielsen, M. J. *Org. Chem.* **2022**, *87*, 5419–5423. doi:10.1021/acs.joc.1c02975
9. Ghanim, A. M.; Rezq, S.; Ibrahim, T. S.; Romero, D. G.; Kothayer, H. *Eur. J. Med. Chem.* **2021**, *219*, 113457. doi:10.1016/j.ejmech.2021.113457

10. Marra, I. F. S.; de Almeida, A. M.; Silva, L. P.; de Castro, P. P.; Corrêa, C. C.; Amarante, G. W. *J. Org. Chem.* **2018**, *83*, 15144–15154. doi:10.1021/acs.joc.8b02430
11. Nam, N. L.; Grandberg, I. I.; Sorokin, V. I. *Chem. Heterocycl. Compd.* **2000**, *36*, 281–283. doi:10.1007/BF02256864
12. Li, Y.; Huang, X.; He, J.; Peng, S.; Wang, J.; Lang, M. *Adv. Synth. Catal.* **2023**, *365*, 490–495. doi:10.1002/adsc.202201335
13. Shi, F.; Zhang, J.; Tu, S.; Jia, R.; Zhang, Y.; Jiang, B.; Jiang, H. *J. Heterocycl. Chem.* **2007**, *44*, 1013–1017. doi:10.1002/jhet.5570440506
14. Minami, S.; Tomita, M.; Kawaguchi, K. *Chem. Pharm. Bull.* **1972**, *20*, 1716–1728. doi:10.1248/cpb.20.1716


# Copies of NMR spectra




**Figure S1:**  $^1\text{H}$  NMR spectrum of compound **3a** (DMSO- $d_6$ ).




**Figure S2:** <sup>13</sup>C NMR spectrum of compound 3a (DMSO-*d*<sub>6</sub>).




**Figure S3:**  $^1\text{H}$  NMR spectrum of compound **4a** ( $\text{CDCl}_3$ ).




**Figure S4:**  $^{13}\text{C}$  NMR spectrum of compound **4a** ( $\text{CDCl}_3$ ).




**Figure S5:**  $^1\text{H}$  NMR spectrum of compound **4b** ( $\text{CDCl}_3$ ).




**Figure S6:**  $^{13}\text{C}$  NMR spectrum of compound **4b** ( $\text{CDCl}_3$ ).




**Figure S7:**  $^1\text{H}$  NMR spectrum of compound **4c** ( $\text{CDCl}_3$ ).




**Figure S8:**  $^{13}\text{C}$  NMR spectrum of compound **4c** ( $\text{CDCl}_3$ ).




**Figure S9:**  $^1\text{H}$  NMR spectrum of compound **4d** ( $\text{DMSO}-\text{d}_6$ ).




**Figure S10:**  $^{13}\text{C}$  NMR spectrum of compound **4d** (DMSO- $d_6$ ).




**Figure S11:**  $^1\text{H}$  NMR spectrum of compound **4e** ( $\text{CDCl}_3$ ).




**Figure S12:**  $^{13}\text{C}$  NMR spectrum of compound **4e** ( $\text{CDCl}_3$ ).




**Figure S13:** <sup>1</sup>H NMR spectrum of compound **4f** (CDCl<sub>3</sub>).




**Figure S14:**  $^{13}\text{C}$  NMR spectrum of compound **4f** ( $\text{CDCl}_3$ ).




**Figure S15:**  $^1\text{H}$  NMR spectrum of compound **4g** ( $\text{CDCl}_3$ ).




**Figure S16:**  $^{13}\text{C}$  NMR spectrum of compound **4g** ( $\text{CDCl}_3$ ).




**Figure S17:**  $^1\text{H}$  NMR spectrum of compound **4h** ( $\text{CDCl}_3$ ).




**Figure S18:**  $^{13}\text{C}$  NMR spectrum of compound **4h** ( $\text{CDCl}_3$ ).




**Figure S19:**  $^{13}\text{C}$  NMR spectrum of compound **4i** (DMSO- $d_6$ ).




**Figure S20:** <sup>13</sup>C NMR spectrum of compound 4i (DMSO-*d*<sub>6</sub>).




**Figure S21:**  $^1\text{H}$  NMR spectrum of compound **9a** ( $\text{CDCl}_3$ ).



**Figure S22:**  $^{13}\text{C}$  NMR spectrum of compound **9a** ( $\text{CDCl}_3$ ).



**Figure S23:**  $^1\text{H}$  NMR spectrum of compound **10a** ( $\text{CDCl}_3$ ).



**Figure S24:**  $^{13}\text{C}$  NMR spectrum of compound **10a** ( $\text{CDCl}_3$ ).